

Rhythm Pharmaceuticals 2023 Methodological Note - ABPI Disclosure Reporting

Tax/VAT considerations:	Yearly amounts for each reportable HCP/HCO is disclosed without VAT
Currency (including conversion rates):	All reported amounts are in British pounds. If the payment is made in another currency, the amount is converted to British Pounds with the rate on the date of the payment.
Transfer of Value Date:	<p>Relates to disclosures for the period August 2023-December 2023</p> <p>For payments related to contracts and services reimbursed or paid directly to the HCP/HCO (check or cash equivalent), the payment date is utilised for reporting.</p> <p>For in-direct expenses provided in-kind to an HCP (such as travel and lodging) provided on behalf of Rhythm, the date that the HCP received the expense is the date utilised for reporting.</p>
Multi-year contracts:	The Company reports all payments made to the reported HCPs/HCOs during the submission year. If a contract contemplated payments to be made in subsequent calendar years, those payments will be reflected in those subsequent calendar years' filings.
Cross Border Payments:	The Company will disclose based on the principal address of the HCP/HCO regardless of the location where the payment was made.
Consent:	The contracts for the reported HCPs/HCOs include consent language between the Company and the HCP/HCOs. By signing the contract, the HCP/HCO is consenting to the disclosure of transfers of value. The Company does not require consent to be obtained in a stand-alone document.
Members of the Public & Patient Organisation Reporting	Rhythm will fulfill ABPI's requirements for Transparency to disclose fees for contracted services made to certain members of the public and to Patient Organizations in the UK.
Additional notes:	None